December 28, 2016
Authored and Edited by Jonathan J. Fagan; Elizabeth D. Ferrill; Jeff T. Watson
In Medgraph, Inc. v. Medtronic, Inc., No. 15-2019 (Fed. Cir. Dec. 13, 2016), the Federal Circuit affirmed the district court’s summary judgment of noninfringement despite recent changes in the law governing direct infringement. Direct infringement of a method claim requires that a single entity or group of entities perform each step of the method. The legal definition of what may be attributed to a “single entity,” however, changed during this case’s pendency. Before the district court granted summary judgment to accused infringer Medtronic, the law attributed third-party acts to an accused infringer if the third party acted as the accused’s agent or in a contractual relationship with the accused. After the grant of summary judgment, the Federal Circuit broadened this standard to include instances when an accused infringer “conditions participation in an activity or receipt of a benefit upon performance of a step or steps” of the method.
Although a change in law normally compels remand, the Court found that patent owner Medgraph produced no facts showing that it could meet the new standard in this case. More specifically, the Court found that—despite extensive discovery—Medgraph presented no facts showing that Medtronic conditioned participation or receipt of a benefit on performance of any of the claimed method’s steps. Additionally, Medgraph identified no potential avenue for discovering additional facts relevant to this inquiry.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
June 13, 2024
Webinar
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.